Skip to content

NeoGenomics

US · NEO #2660 by market cap Listed 1970
14.82 -0.27 -1.79%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 15.00 -0.60%
After-hours 14.79 -0.20%
19.919.2714.822026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NEO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +14.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 10.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth C

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 12.6% Better than 71%
Free cash flow CAGR (3Y) -37.9% Better than 8%
Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 43.2% Better than 53%
Operating margin -12.1% Better than 14%
Net margin -14.9% Better than 14%
Return on equity -12.4% Better than 19%
Return on invested capital -8.2% Better than 19%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -12.7% Better than 44%
6-month return 60.6% Better than 97%
12-month return (ex latest month) 42.8% Better than 80%
Distance below 52-week high 26.5% Better than 48%
Financial Health C-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.3x Better than 82%
Debt to assets 30.1% Better than 41%
Interest coverage -28.4x Better than 9%
Free cash flow / net income 41.7% Better than 11%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 77.8% Better than 57%
Upside to average target 66.7% Better than 75%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.49%
1M -10.83%
3M -10.34%
6M +66.52%
YTD +26.02%
1Y +39.81%
3Y -24.04%
5Y -62.98%

Key statistics

Price & volume

Prev close
15.09
Open
14.86
Day range
14.63 - 15.14
Avg price
14.83
Volume
1.18M
Turnover
17.46M
Amplitude
3.38%
52-week range
7.07 - 20.15

Valuation

P/E
-17.64
P/E (TTM)
-61.75
P/B
2.39
EPS
-0.84
Net profit
-108.69M
Net assets
800.66M

Share structure

Market cap
1.92B
Float cap
1.75B
Shares out
129.39M
Float shares
118.11M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 59% of range
7.07 20.15

26.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-257.28K net over the window

Short interest

Shares short
13.13M
As of
2026-10-30

Frequently asked questions

What is the current stock price of NeoGenomics (NEO)?

NeoGenomics last traded at 14.82. This page shows a periodic quote snapshot. Check the displayed quote time.

What is NeoGenomics's market cap?

About 1.92B.

What is the P/E ratio of NeoGenomics?

The trailing twelve-month P/E is -61.75. The Valuation tab shows it against the stock's own five-year range.

Does NeoGenomics pay a dividend?

NeoGenomics does not currently pay a regular dividend.

Is NeoGenomics a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 24.71, which implies 66.7% upside from the current price. This is not investment advice.

What is NeoGenomics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates NeoGenomics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

NeoGenomics discussion 0 comments

Add a comment